Evidence map›Paper›PMID 34051863›Full record

ArticleStem cell research & therapy2021

A dual cardiomyocyte reporter model derived from human pluripotent stem cells.

Yuqian Jiang, Xiaoping Bao, Xiaojun Lance Lian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Yuqian JiangDepartment of Biomedical Engineering, Pennsylvania State University, University Park, PA, 16802, USA.
Xiaoping BaoDavidson School of Chemical Engineering, Purdue University, West Lafayette, IN, 47907, USA. bao61@purdue.edu.
Xiaojun Lance LianDepartment of Biomedical Engineering, Pennsylvania State University, University Park, PA, 16802, USA. Lian@psu.edu.ORCID 0000-0002-9161-1004
Pennsylvania State University · USPurdue University West Lafayette · US

Funding

Stem cell immunoengineering for universal cardiac therapy via CRISPR-Cas9R21EB026035 · NIBIB · PENNSYLVANIA STATE UNIVERSITY, THE · PI LIAN, XIAOJUN · 2018 to 2020
$567k
ModRNA-based Direct Programming of Universal Donor hiPSCs into Immune Evasive Beta CellsR56DK133147 · NIDDK · PENNSYLVANIA STATE UNIVERSITY, THE · PI LIAN, XIAOJUN · 2023 to 2024
$465k
Contribution of IL-32 gene expression to viral persistenceR21AI149312 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAMERON, CRAIG E. · 2020 to 2021
$432k
NIBIB NIH HHS R21 EB026035NIDDK NIH HHS R56 DK133147
6 · The paper itself

Abstract

Cardiovascular diseases (CVD) remain the leading cause of death in the USA. Cardiomyocytes (CMs) derived from human pluripotent stem cells (hPSCs) provide a valuable cell source for regenerative therapy, disease modeling, and drug screening. Here, we established a hPSC line integrated with a mCherry fluorescent protein driven by the alpha myosin heavy chain (aMHC) promoter, which could be used to purify CMs based on the aMHC promoter activity in these cells. Combined with a fluorescent voltage indicator, ASAP2f, we achieved a dual reporter CM platform, which enables purification and characterization of CM subtypes and holds great potential for disease modeling and drug discovery of CVD.

Indexed as

Myocytes, CardiacPluripotent Stem CellsCell DifferentiationHumansMyosin Heavy ChainsMyosin Heavy ChainsAlpha MHC promoterASAP2f indicatorAtrial or ventricular cardiomyocytesDual reporterHuman pluripotent stem cells

Identifiers

PMID34051863
PMCPMC8164304
OpenAlexW3164154683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.